TDSGF (Telo Genomics) Shares Buyback Ratio %: -0.41 (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Telo Genomics Shares Buyback Ratio %?

Telo Genomics TDSGF Shares Buyback Ratio % is -0.41 as of Sep. 05, 2026. The stock has 2 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Telo Genomics's current shares buyback ratio was -0.41%.

Telo Genomics Shares Buyback Ratio % Related Terms

Telo Genomics Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Telo Genomics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics Shares Buyback Ratio % Chart

Telo Genomics Annual Data
Trend Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -34.53 -6.99 -19.75 -4.78 -34.15

Telo Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.41 0.00 0.00

Telo Genomics Shares Buyback Ratio % Calculation

Telo Genomics's Shares Buyback Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2024 ) - Shares Outstanding (EOP) (A: Jun. 2025 )) / Shares Outstanding (EOP) (A: Jun. 2024 )
=(74.560 - 100.019) / 74.560
=-34.15%

Telo Genomics's Shares Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2025 ) - Shares Outstanding (EOP) (A: Mar. 2026 )) / Shares Outstanding (EOP) (A: Dec. 2025 )
=(100.430 - 100.430) / 100.430
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -0.41 mean?
Telo Genomics (TDSGF) has a Shares Buyback Ratio % of -0.41 as of Sep. 05, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Telo Genomics and its competitors.
Is Telo Genomics' Shares Buyback Ratio % too high?
Telo Genomics' current Shares Buyback Ratio % is -0.41.
How does Telo Genomics' Shares Buyback Ratio % compare to TMO and DHR?
Telo Genomics' Shares Buyback Ratio % of -0.41 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Medical Diagnostics & Research company?
A good Shares Buyback Ratio % depends on the Medical Diagnostics & Research industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Telo Genomics and its competitors. Telo Genomics's current Shares Buyback Ratio % is -0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current Shares Buyback Ratio % of -0.41. The current Shares Buyback Ratio % is -0.41. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current Shares Buyback Ratio % is -0.41 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telo Genomics Business Description

Other Exchanges 3D0A:GermanyTELO:Canada
Address 2255 York Avenue, Suite 203, Vancouver, BC, CAN, V6K 1C5
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.